

Dear Shareholders,

Medicortex is approaching a defining phase in the company's development.

Over recent years, we have systematically advanced our position within the growing field of brain injury diagnostics and neurodegenerative disease research. Through focused scientific development, disciplined capital allocation, and continued strengthening of our intellectual property portfolio, we believe Medicortex is increasingly positioned to transition from an early-stage research company into a commercially focused Nordic life science growth company.

The global need for improved diagnostics and treatment solutions in traumatic brain injury remains significant and underserved. At the same time, healthcare systems, regulators, and investors are placing increased emphasis on technologies capable of enabling earlier detection, precision medicine, and improved neurological outcomes. We believe these structural market trends create substantial long-term opportunities for Medicortex.

During the past year, the company has continued to advance key development initiatives while simultaneously evaluating strategic alternatives to support future expansion and shareholder value creation. This includes preparations associated with accessing public capital markets.

A potential listing transaction would represent an important strategic milestone for Medicortex. We believe a public market platform could provide:

1. Improved access to long-term growth capital;
2. Increased visibility among Nordic and international life science investors;
3. Enhanced strategic flexibility in partnership and commercialization discussions; and
4. A stronger foundation for accelerating operational and clinical development activities.

Importantly, our objective is not simply to achieve a listing, but to build a sustainable, high-quality growth company with strong scientific credibility, scalable commercial potential, and long-term shareholder alignment.

Medicortex continues to operate with a focused and capital-efficient strategy. Our priorities remain clear:

1. Advancing our proprietary technology portfolio;
2. Expanding and protecting intellectual property rights;
3. Pursuing strategic partnerships and financing opportunities;
4. Strengthening regulatory and commercialization readiness; and
5. Building long-term value through disciplined execution and team of excellency

The Board and management team remain highly encouraged by the company's progress and future opportunities. While biotechnology development inherently involves risk and requires patience, we believe Medicortex is entering an increasingly attractive position within the Nordic small-cap life science landscape.

We would like to thank our shareholders for their continued support and confidence. Your commitment has enabled the company to reach this important stage, and we look forward to sharing further progress as Medicortex continues its journey toward becoming a publicly visible and internationally recognized biotechnology company.

Sincerely,

Anna Tenstam

Chairman

Medicortex Finland Oyj